Publications

Improving Clinical Trial ROI with Medication Adherence Management

Study power is the Holy Grail of clinical trials, setting drug developers on the quickest path to market – but non-adherence causes costly detours. When participants do not take their medication as specified in the study protocol, it can result in underestimated drug efficacy, delay the approval of investigational products, and contribute to rising costs.…

Read More

Happy Holidays!

As we prepare to wrap up the year, we wanted to take an opportunity to reflect on the past twelve months. While COVID-19 had an unprecedented impact on our day-to-day lives, we can take solace in the fact that the pandemic served as a catalyst for drug development to take a huge leap forward. We…

Read More

We see an uptake in Remote, Decentralized and Hybrid Trials. Do you?

We are soon leaving a very difficult year in all aspects. We lived with global pandemic and civil troubles in the news all year long. However, our Scientific Lead, Bernard Vrijens sees an uptake in remote, decentralized, and hybrid trials. Because humans will always learn, and innovate from difficulties. That’s exactly what PharmaVoice magazine tried…

Read More

AARDEX announces the world’s first DIGITAL MEDICATION ADHERENCE MONITORING solution fully integrated in the clinical trial platform by a top 10 pharma company.

AARDEX is proud to announce the integration of its MEMS® Adherence Software by a major pharmaceutical company. It’s the first end-to-end integration of electronically compiled dosing histories using smart packages from interactive response technology (IRT) into electronical data capture systems (EDC) to improve medication adherence data accuracy in clinical trials. This collaboration, initiated in 2015,…

Read More

AARDEX Group announces the opening of a new office in the U.S.

By establishing itself in the U.S., the Group aims to strengthen its business and maintain its position as market leader in digital adherence monitoring systems. Joe Keenan will lead the business development for the pharma and biotech industry in North America. With over 70% of AARDEX’s customers based in the U.S., this new office will support…

Read More